NASDAQ:ABMD
Delisted
ABIOMED Stock News
$381.02
+0 (+0%)
At Close: Mar 20, 2023
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
03:07pm, Tuesday, 08'th Nov 2022 The Motley Fool
These robust businesses will be around well beyond the next 10 years.
3 No-Brainer Stocks to Buy in a Downturn
02:45pm, Tuesday, 08'th Nov 2022 The Motley Fool
These companies thrive when others falter.
Johnson & Johnson's Big Purchase, Amazon's New Moves, and More
02:45pm, Saturday, 05'th Nov 2022 The Motley Fool
Plus, we run through some shortcuts that could help you with your financial planning.
Wall Street Breakfast: What Moved Markets
12:21pm, Saturday, 05'th Nov 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
11:25am, Saturday, 05'th Nov 2022 The Motley Fool
The $16.6 billion acquisition shakes up MedTech.
Beat the Dow Jones With This Unstoppable Dividend Stock
10:00am, Saturday, 05'th Nov 2022 The Motley Fool
Johnson & Johnson has outperformed the Dow so far this year.
Is Johnson & Johnson's Purchase of Abiomed Good for Investors?
07:25am, Saturday, 05'th Nov 2022
The $16.6 billion acquisition shakes up MedTech.
Beat the Dow Jones With This Unstoppable Dividend Stock
06:00am, Saturday, 05'th Nov 2022
Johnson & Johnson has outperformed the Dow so far this year.
What Happened This Week: Buyback Tax Trend And All Atwitter @ Twitter
08:35pm, Friday, 04'th Nov 2022 Investing.com
5 Analysts Have This to Say About Abiomed
06:08pm, Wednesday, 02'nd Nov 2022 Benzinga
Over the past 3 months, 5 analysts have published their opinion on Abiomed (NASDAQ:ABMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
02:06pm, Wednesday, 02'nd Nov 2022 Benzinga
Upgrades
According to Evercore ISI Group, the prior rating for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) was changed from In-Line to Outperform. In the third quarter, BioCryst Pharmaceuticals showed
Is Johnson & Johnson an Underrated Growth Stock?
09:50am, Wednesday, 02'nd Nov 2022 The Motley Fool
Johnson & Johnson trades at a modest earnings multiple, and it may warrant a premium.
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
09:07am, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Abiomed, Inc. (NASDAQ: ABMD) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson & Johnson announced it will acquire the company . Also, the company reported better-than-expec
Gartner, Sony, Uber And Other Big Gainers From Tuesday
06:57am, Wednesday, 02'nd Nov 2022 Benzinga
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.
Abiomed, Inc. (NASDAQ: ABMD) s
Why Abiomed Stock Skyrocketed Today
08:49pm, Tuesday, 01'st Nov 2022 The Motley Fool
A healthcare titan wants to acquire the medical technology specialist for a whopping $16.6 billion.
